# reload+after+2024-01-21 08:47:52.157403
address1§2200 Pennsylvania Avenue NW
address2§Suite 300E
city§Washington
state§DC
zip§20037
country§United States
phone§202 734 3400
fax§202 296 1450
website§https://www.vandapharma.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs worldwide. The company's marketed products include HETLIOZ to treat non-24-hour sleep-wake disorders; and Fanapt oral tablets for the treatment of schizophrenia. Its pipeline products include HETLIOZ (tasimelteon) to treat jet lag disorder, insomnia, delayed sleep phase disorder, sleep disturbances in autism spectrum disorder, and pediatric Non-24; Fanapt (iloperidone) for the treatment of bipolar I disorder and Parkinson's disease psychosis, as well as a long acting injectable (LAI) formulation to treat schizophrenia; and Tradipitant (VLY-686), a small molecule neurokinin-1 receptor (NK-1R) antagonist to treat gastroparesis, motion sickness, atopic dermatitis, and COVID-19 pneumonia. The company's pipeline products also include VTR-297, a small molecule histone deacetylase inhibitor to treat hematologic malignancies and with potential use as a treatment for various oncology indications; VQW-765, a small molecule nicotinic acetylcholine receptor partial agonist to treat performance anxiety and psychiatric disorders; VHX-896, an active metabolite of iloperidone; and antisense oligonucleotide molecules. In addition, it offers a portfolio of cystic fibrosis transmembrane conductance regulator activators and inhibitors that include VSJ-110 for the treatment of dry eye and ocular inflammation; and VPO-227 for the treatment of secretory diarrhea disorders comprising cholera. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.
fullTimeEmployees§290
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Mihael H. Polymeropoulos M.D.', 'age': 63, 'title': 'Founder, President, CEO & Chairman of The Board', 'yearBorn': 1960, 'fiscalYear': 2022, 'totalPay': 1511670, 'exercisedValue': 1124727, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Kevin Patrick Moran', 'age': 39, 'title': 'Senior VP, CFO & Treasurer', 'yearBorn': 1984, 'fiscalYear': 2022, 'totalPay': 660215, 'exercisedValue': 56149, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Timothy  Williams', 'age': 47, 'title': 'Senior VP, General Counsel & Secretary', 'yearBorn': 1976, 'fiscalYear': 2022, 'totalPay': 724380, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Joakim  Wijkstrom', 'age': 57, 'title': 'Senior VP & Chief Marketing Officer', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 836364, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Gunther  Birznieks', 'age': 53, 'title': 'Senior Vice President of Business Development', 'yearBorn': 1970, 'fiscalYear': 2022, 'totalPay': 690831, 'exercisedValue': 9250, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Scott L. Howell', 'title': 'Chief People Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Elizabeth  Van Every', 'title': 'Head of Corporate Affairs', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
auditRisk§3
boardRisk§6
compensationRisk§5
shareHolderRightsRisk§5
overallRisk§5
governanceEpochDate§1704067200
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.69
priceToSalesTrailing12Months§1.1378709
currency§USD
dateShortInterest§1702598400
forwardEps§-0.46
pegRatio§-11.72
exchange§NGM
quoteType§EQUITY
shortName§Vanda Pharmaceuticals Inc.
longName§Vanda Pharmaceuticals Inc.
firstTradeDateEpochUtc§1144848600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§587a557b-da73-3a2f-b90a-0a189a3b4d7d
gmtOffSetMilliseconds§-18000000
targetHighPrice§4.25
targetLowPrice§4.25
targetMeanPrice§4.25
targetMedianPrice§4.25
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§6.119
earningsGrowth§-0.959
grossMargins§0.91705
ebitdaMargins§0.01079
trailingPegRatio§None
